SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals will be presenting at the Fifth Annual JMP Securities Research conference March 8 at 4:25 p.m. pacific time. Michael Grey, president and chief executive officer of SGX Pharmaceuticals, will provide a corporate overview including highlights of the company’s lead drug development candidate, Troxatyl(TM), currently in a pivotal phase II/III trial for the treatment of third-line acute myelogenous leukemia. The conference takes place at the Ritz-Carlton hotel in San Francisco March 7-9.
The live presentation will be webcast, and a recording will be made available for 90 days following the event. The audio webcast will be accessible through the Investors page of the Company’s website found at http://www.sgxpharma.com.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. More information can be found at www.sgxpharma.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to SGX’s research and drug discovery and development programs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, and litigation. For a discussion of these and other factors, please refer to the risk factors section of the final prospectus from SGX’s initial public offering filed with the United States Securities and Exchange Commission on February 1, 2006 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
SGX Pharmaceuticals
CONTACT: Jason Spark of Porter Novelli Life Sciences, +1-858-527-3491,jspark@pnlifesciences.com, for SGX Pharmaceuticals
Web site: http://www.sgxpharma.com/
